Strategic & Scientific Advisory Board

Beverly Davidson, Ph.D.

 
 
 

Beverly Davidson, Ph.D., Director of the Raymond G Perelman Center for Cellular and Molecular Therapeutics and Arthur V. Meigs Chair in Pediatrics, Children’s Hospital of Philadelphia; Professor in the Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. Dr. Davidson’s research focuses on the pathogenesis and therapy of hereditary neurogenetic diseases and the role of noncoding RNAs in neural development. She is an internationally known expert in the study of inherited neurological diseases and the development of molecular therapies. Dr. Davidson has been named a fellow by the American Association for the Advancement of Science, received the NIH Mathilde Solowey Award, was elected to the Advisory Council for the American Society of Gene and Cell Therapy and NINDS council, and was past chair of the Medical Sciences Section for the American Association for the Advancement of Science.

 
 
 
 
 

Kenneth Fischbeck, M.D.

 
 
 

Kenneth Fischbeck, M.D., received A.B. and A.M. degrees from Harvard University and a M.D. degree from Johns Hopkins. After a medical internship at Case Western Reserve University and a neurology residency at the University of California in San Francisco, he did postdoctoral research on muscular dystrophy at the University of Pennsylvania. In 1982, he joined the faculty in the Neurology Department at the University of Pennsylvania Medical School. In 1998, he joined the National Institute of Neurological Disorders and Stroke (NINDS) as Chief of the Neurogenetics Branch. He received the Cotzias Award from the American Academy of Neurology and the Jacoby Award from the American Neurological Association, and he was elected to the Institute of Medicine. His research group is identifying the causes and studying the mechanisms of hereditary neurological and neuromuscular diseases with the goal of developing effective treatment for these disorders.

 
 
 
 
 

Louis M. Kunkel, Ph.D.

 
 
 

Louis M. Kunkel, Ph.D., Past Chief of the Division of Genetics and currently a member of the Division of Genetics and Genomics, Boston Children’s Hospital. Professor of Pediatrics and Genetics, Harvard Medical School; Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Worchester MA; HHMI Investigator, 1987-2010; and Member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Kunkel is an internationally recognized geneticist with decades of experience and scientific success in the understanding of the basis for muscular dystrophies. Dr. Kunkel is responsible for the identification of the gene and encoded protein, dystrophin. He has received numerous awards and honors for scientific leadership and achievement and currently serves as the committee chair for the Muscular Dystrophy Association (MDA), a committee he has been a member of for over 15 years.

 
 
 
 
 

MATTHEW WOOD, M.D., Ph.D.

 
 
 

Matthew Wood, M.D., Ph.D., is a Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford, and directs the Laboratory of RNA biology and Neuromuscular Disease. Dr. Wood is a leading pioneer in the field of oligonucleotide therapies and co-leads the International MDEX Consortium, a major international translational medicine collaboration to develop oligonucleotide treatments for DMD and related neuromuscular conditions, with Dr. Francesco Muntoni of University College London. Sarepta’s EXONDYS 51 was the first oligonucleotide worked on by this Consortium. Dr. Wood is an executive member of the global alliance TREAT-NMD. Dr. Wood serves as a Director of several organizations, including the Oxford MDUK Centre for Translational Neuromuscular Science, the University of Oxford’s technology transfer organization, Oxford University Innovation, and Evox Therapeutics, a company he founded based on his work with exosomes. He currently serves as the Deputy Head of the Medical Sciences Division of the University of Oxford, and holds a Director role on the Board of MedCity.